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Abstract
Introduction: Helicobacter pylori is a major cause of more than 80% of 
chronic active gastritis and other gastrodeudonal diseases worldwide. 
Successful treatment of H. pylori routinely requires the use of multiple 
agents with different mechanisms including compounds inhibiting 
acid secretion in conjunction with antibiotics. However, recent data 
showed the emergence of resistant clinical strains particularly against 
metronidazole and clarithromycin. The aim of this study is to determine 
the prevalence of and the susceptibility of H. pylori isolates recovered 
from patients with gastrodeudonal diseases to several antimicrobial 
agents.
Materials and Methods: A prospective study has been conducting on 
Jordanian patients attended the gastrointestinal unit of the Jordan 
university hospital starting from 2014-2015 with gastroduodenal 
diseases. Antral and corpus mucosal biopsies from the stomach of 
each patient were used for the isolation of H. pylori on selective 
culture media. Presumptive H. pylori colonies were subsequently 
confirmed by biochemical tests and standard 16S rDNA PCR assay. 
The antimicrobial susceptibility testing was performed by standard 
agar diffusion methods according to CLSI. Subsequently, MICs were 
determined by E test and standard agar dilution method. Molecular 
typing of the clinical strains was performed using multiplex PCR for 
the detection of vacA and cagA genotypes. Metronidazole resistance 
was characterized by molecular methods for the detection of rdxA 
gene mutations.
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Introduction
Recently, the medical community has been in-
creasingly interested in Helicobacter pylori (H pylori) 
related diseases as several studies have been report-
ing a major role of H. pylori in chronic gastritis and 
peptic ulcer worldwide [1, 2]. Colonization of the 
gastric mucosa with H. pylori constitutes a major 
risk factor in the pathogenesis of gastric cancer and 
gastric mucosa-associated lymphoid tissue (MALTo-
ma) [3-5]. 
H. pylori is equipped with an armamentarium of 
biological factors that enable this microaerophilic 
bacterium to survive in the harsh conditions pres-
ent in human stomach. For instance, all strains of 
H. pylori possess a unique stable urease enzyme 
which is used to neutralize the stomach acidity and 
provide a suitable pH for the growth of this bacte-
rium. In addition, the presence of numerous bind-
ing proteins and adhesion molecules ensure optimal 
colonization of H. pylori in the gastric mucosa [6]. 
Among the H. pylori virulence factors, cytotoxin A 
(CagA) and vacuolating cytotoxin A (VacA) are the 
most studied since the production of these tox-
ins increases the risk for gastric atrophy, intestinal 
metaplasia and gastric carcinoma [7, 8]. However, 
genetic variation within the genes encoding these 
virulence factors contributes to differences in the 
pathogenicity of strains [9]. It has been reported 
that a round 70% of the H. pylori strains isolated 
in the western countries possess the cagA gene 
while higher prevalence of cagA-positive strains is 
Results: Among 72 symptomatic patients, 13(23%) patients showed 
positive H. pylori infection by both rapid urease test and culture. The 
antibiotic susceptibility profile showed that all of the isolates were 
sensitive to amoxicillin. Resistance to, clarithromycin, ciprofloxacin and 
levofloxacin were observed in 15%, 23% and 8% of the isolates 
respectively while 92% of the strains were resistant to metronidazole 
(MIC ≥ 32ug/ml). Metronidazole resistance due to mutations in rdxA 
gene was only observed in one strain (8%) suggesting other resistance 
mechanisms. Correlation between antibiotic resistance and virulence 
factors was statistically not significant (p > 0.05).
Conclusion: The present study showed that the prevalence of 
metronidazole resistance among clinical isolates of H. pylori is very 
high. Lower resistance to other antibiotics are reported. Concern 
should be taken into consideration when triple therapy is used for 
the treatment of H. pylori in our region.
Keywords: Helicobacter pylori, Jordanian patients, Antibiotic resistance, 
Metronidazole
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reported in East Asian countries [10, 11]. On the 
other hand, vacA is present in approximately all H. 
pylori strains however, allelic variation in three main 
genetic regions encoding and regulating this protein 
has been observed [12, 13]. Depending on the type 
and combinations of vacA different alleles, distinct 
abilities of vacA to induce vacuolation in epithelial 
cells can occur [14]. Associations between infection 
with strains containing certain vacA alleles and in-
creased risk for progression of gastric precancerous 
lesions and for gastric carcinoma were also reported 
[15, 16].
The eradication of H. pylori and attenuating its as-
sociated virulence factors can contribute to improve 
clinical conditions of the patients infected with this 
bacterium including accelerating peptic ulcer heal-
ing and minimizing the recurrence of gastric cancer. 
Current approaches for effective eradication of H. 
pylori include the use of at least two antibiotics and 
a proton pump inhibitor (triple and more recently 
quadruple therapy [17, 18]. Triple therapy, including 
two antibiotics, amoxicillin and clarithromycin, and 
a proton pump inhibitor given for a week has been 
recommended as the treatment of choice [19]. Other 
treatments have also been proposed, including met-
ronidazole, as well as tetracycline, fluoroquinolones, 
and rifamycins. However, due to the emergence of 
antibiotic resistance among H. pylori clinical strains 
particularly against clarithromycin, and to a lesser 
extent metronidazole, higher rates of treatment fail-
ure of triple therapy were reported [21, 22]. Global 
studies in Europe reported a prevalence of H. pylori 
resistance to clarithromycin among adults and chil-
dren of approximately 20%. In contrast, higher rates 
of resistance against metronidazole were reported 
in Europe and USA [23, 24]. 
Only few data regarding the resistance of H. py-
lori clinical strains to the conventional antimicrobial 
agents used in the clinical practice were reported 
which might be due to the technical difficulties to 
isolate and perform the standard methods for anti-
microbial susceptibility testing on H. pylori. Our aim 
is to study the prevalence of H. pylori resistance to 
these various antibiotics especially in light of the re-
sistance mechanism using both microbiological and 
molecular methods in addition to characterize the 
virulence factors and their possible association with 
antibiotic resistance among H. pylori strains.
Materials and methods
Patients and specimens. Antral and corpus 
mucosal gastric biopsies from stomach of 72 Jor-
danian patients attending the gastrointestinal unit 
of the Jordan University Hospital presented with any 
of the following clinical manifestations active gas-
tritis, peptic ulcer or gastric cancer were obtained. 
Informed written consent was obtained from all 
patients participating in this study after ethical ap-
proval has been provided. Biopsies were transferred 
into 4 ml aliquots containing 1% Proteose Peptone 
(Oxoid, UK) for transport purposes.
Isolation and identification of H. pylori. For 
optimal recovery of clinical strains of H. pylori, all 
biopsy tissues were homogenized using a tissue ho-
mogenizer (IKA, Germany) and aliquots of 100 µl 
of the homogenate of each sample were inoculated 
into Columbia blood agar base (Oxoid, UK) contain-
ing 7 % laked horse blood and Helicobacter pylori 
selective supplement (Dent, Oxoid, UK) [25]. All of 
the plates were incubated at 37°C under microaero-
philic conditions using CampyGen atmosphere gen-
erating system (Oxoid, UK) in anaerobic Jars for 5-7 
days. Growth of H. pylori was confirmed according 
to colony morphology, Gram staining, microaero-
philic growth at 37°C, oxidase, catalase and urease 
and subsequently by standard PCR of 16S rDNA 
test [26]. H. pylori cultures were stored at -70°C in 
Trypticase soy broth (Oxoid, UK) containing 10% v/v 
fetal calf serum (PAA, Austria) and 15% glycerol.
Antimicrobial susceptibility testing and MIC 
measurements. Bacterial suspensions were pre-
pared to the 2 McFarland’s standard and subse-
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quently uniformly spread on a solid growth medium 
in a Petri dish. Antibiotic discs including amoxicillin 
(25 µg), metronidazole (5 µg), clarithromycin (15 µg), 
ciprofloxacin (5 µg), and levofloxacin (5 µg) (Mast, 
USA) were used. Plates were incubated for 5-7 days 
under appropriate cultivation conditions. Antibacte-
rial activity was determined by the production of 
an inhibition zone around the disc. The minimal in-
hibitory concentrations (MICs) of each antimicrobial 
agent were determined by both E- test (Mast, USA) 
and by the two fold agar dilution method according 
to CLSI recommendations [27]. Antimicrobial agents 
were provided as powder from local pharmaceuti-
cal manufacturers and dissolved in distilled water 
for stock solutions. Next, two fold serial dilutions 
of each antimicrobial agent incorporated to molten 
Columbia blood agar plates supplemented with 7% 
(v/v) horse blood were prepared. Spots of H. pylori 
(1x 105 CFU) were applied on the surface of each 
plate and the growth of visible colonies was de-
termined after 5-7 days of incubation at 37°C un-
der microaerophilic conditions. MIC was recorded 
as the lowest concentration that inhibited visible 
growth of H. pylori in the agar dilution method and 
by measuring the ellipse edge intersects the strip in 
E-test. Triplicates of each antimicrobial agent were 
performed and the average of the results was tak-
en. The resistance breakpoints of antibiotics were 
defined for amoxicillin ≥ 0.5 µg/ml, metronidazole 
> 8.0 µg/ml, ciprofloxacin and levofloxacin > 1.0 µg/
ml and clarithromycin ≥ 1.0 µg/ml.
Detection of cagA and Vac A alleles. Detec-
tion of CagA gene, and VacA allele variation was 
performed as described by Atherone et al., 1995 
and Zheng et al., 2000 with slight modifications [28, 
29] (Table 1). In brief, multiplex PCR was performed 
with the primers of concentrations of 0.2 µM each 
and 1X ready to use master mix (New England bio-
lab, UK) with adjusted concentration of MgCl2 of 
2.5 µM in a final reaction volume of 50 µl. The 
amplification was performed with the following pa-
rameters; 95°C for 10 min followed by 40 cycles of 
30s at 95°C, 45s at 58°C and 45s at 62°C. Positive 
and negative controls were used in all experiments 
and the PCR amplified products were analyzed by 
2% agarose gel electrophoresis.
Detection of rdx Agene deletion in Metro-
nidazole resistant H. pylori. Detection of NADPH 
nitroreductase was performed by conventional mu-
tagenic-based PCR with the following conditions 
and parameter; reactions were carried out in 25 μl 
mixtures containing 12.5 μl PCR master mix (New 
Table 1.  Oligonucleotide sequences used in this study
Primer name 
Sequence 
5`-3`
Target size (bp)
Annealing 
temp
References
HP1 GCAATCAGCGTCAGTAATGTTC 16S rRNA
521
55 26
HP2 GCTAAGAGATCAGCCTATGTCC
cagA1 TTGACCAACAACCACAAACCGAAG Cag
183
60 29
cagA2 CTTCCCTTAATTGCGAGATTCC
vacA m1 F GGTCAAAATGCGGTCATGG VacA M1 allele
290
56
28
vacA m1 R CCATTGGTACCTGTAGAAAC
vacA m2 F GGAGCCCCAGGAAACATTG vacA M2 allele
352
56
vacA m2 R CATAACTAGCGCCTTGCAC
rdxA F AATTTGAGCATGGGGCAGA NADPH reductase
850
55 30
rdxA R GAAACGCTTGAAAACACCCCT 
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Table 2.  Clinical and epidemiological characteristics of patients enrolled in this study
Characteristics
Culture (+)
Occurrence of H. pylori
Total P value
Culture (–)
Age
15-35 5 13 18
>0.0536-55 4 26 30
56-80 4 20 24
Sex
Male 3 25 28
>0.05
Female 10 34 44
Gastrointestinal complains
Anemia 2 6 8 >0.05
Dyspepsia 2 3 5 < 0.02
Dysphagia 1 3 4 >0.05
Epigastric pain 5 34 39 >0.05
Heartburn 4 4 8 < 0.02
Vomiting 2 6 8 >0.05
Endoscopic finding
Mild gastritis 3 19 22
>0.05
GERD 2 15 17
Erosions and Ulceration 3 19 22
Duodenitis 3 11 14
Use of antibiotics
Yes 3 21 24
>0.05
No 6 42 48
Use of PPI
Yes 7 32 39
>0.05
No 2 31 33
Use of NSAIDs
Yes 2 22 24
>0.05
No 7 41 48
England biolab, UK), 9.5 μl sterile deionized water, 
1 μl template DNA (100 ng) and 1 μl of each oligo-
nucleotide primers (0.4 μM). Initial denaturation at 
94°C for 5 mins followed by 30 cycles of denatur-
ation at 94°C for 45s, annealing for 1min at 55°C, 
extension at 72°C for 30s. The expected fragment 
was 800 bp if the gene is normal and 650 bp if 
the gene is mutated. PCR amplified products were 
analyzed by 1.5% agarose gel electrophoresis [30].
Statistical analysis
The results were statistically analyzed using the 
Chi square or Fisher’s exact test. The level of signifi-
cance was set at p < 0.05.
Results
Prevalence of H. pylori and patients charac-
teristics. A total of 72 patients presented with gas-
troduedenal diseases were included in this Study. 13 
cases (23%) presented positive culture for H. pylori, 
with one of the patients (8%) presenting growth 
only in the biopsy of the gastric corpus, five patients 
(38%) in the biopsy of the antrum, while 7 patients 
(54%) were positive for H. pylori growth in both 
biopsy cultures. In general, statistically significant 
differences were not reported for the prevalence 
of H. pylori as a function of gender, age groups 
and endoscopic findings (p > 0.05) (Table 2). Fur-
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Table 3. Antimicrobial susceptibility profile of H. pylori clinical strains to conventional antibiotics
Antibiotic
Sensitivity to antibiotics
(MIC µg/ml)
Strain number
1 2 3 4 5 6 7 8 9 10 11 12 13
AMX S S S S S S S S S S S S S
CLR S S
R
(8)*
S S S S S S
R
(8)
S S S
CIP S S
R
(4)
S S S S S
R
(4)
R
(16)
S S S
LEV S S S S S S S S S
R
(8)
S S S
MTZ
R
(64)
S R
(128)
R
(64)
R
(64)
R
(32)
R
(32)
R
(64)
R
(64)
R
(128)
R
(64)
R
(64)
R
(64)
AMX= amoxicillin, CLR= clarithromycin, CIP= ciprofloxacin, LEV= levofloxacin, MTZ= metronidazole. R indicates resistant, S indicates 
sensitive
thermore, the presence of H. pylori in patients who 
used antibiotics and or NSAID was not statistically 
significant. Although the rate of H. pylori coloniza-
tion increased with the use of PPI as reported in 
this work, no statistical significance was reported. 
In regards to the clinical manifestations, H. pylori 
colonization was significantly higher in patients pre-
sented with heartburn and dyspepsia (p < 0.05). 
Antimicrobial susceptibility profile of H. 
pylori. All of the tested strains were sensitive to 
amoxicillin with values of MICs range of 0.015-0.03 
µg/ml. Resistance to ciprofloxacin and levofloxacin 
was observed in 23% and 8% respectively (Figure 
1). MIC values of ciprofloxacin resistance in H. py-
lori were 4-16 µg/ml (Table 3). 15% of the strains 
were resistant to clarithromycin with MIC value of 8 
µg/ml. Resistance to metronidazole was dominating 
with 92% of the strains showed moderate to high 
levels of resistance with MIC range of 32-128 µg/ml. 
Characterization of cagA and vacA geno-
types and their relation to antibiotic resistance. 
Molecular analysis of different alleles of the vacA 
Figure 1. Percentages of H. pylori resistant to antimicrobial agents used in this study 
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gene showed that one sample (8%) were found to 
have both m1 and m2 alleles with notable moder-
ate multi-drug resistant behavior against the tested 
antibiotics (Table 4). The majority of the tested H. 
pylori strains possess the m2 allele (78%). No statis-
tical significant association between the vacA allelic 
genotype and resistance to antibiotics or the clinical 
manifestation could be established (p > 0.05).
cagA gene was detected in 46% of the tested 
strains with no correlation to antibiotic resistance 
and clinical manifestations. 
Table 4.  cagA and vacA genotypes of clinical 
strains of H. pylori and their relation 
to the rdxA genetic mutations in 
metronidazole resistance
Strain Genotype
1 cagA+, vacA m1, rdxA 650
2 cagA-, vacA m2, rdxA 800
3 cagA+, vacA m1,m2, rdxA800
4 cagA+, vacA m2, rdxA800
5 cagA-, vacA m2, rdxA 800
6 cagA-, vacA m2, rdxA 800
7 cagA+, vacA m2, rdxA 800
8 cagA+, vacA m1, rdxA 800
9 cagA-, vacAm2, rdxA800
10 cagA-, vacAm2, rdxA800
11 cagA-, vacAm2, rdxA 800
12 cagA+, vacA m2, rdxA800
13 cagA-, vacA m2, rdxA800
rdxA 650: deletion mutation, rdxA 800: normal length gene
Characterization of rdxA mutations in met-
ronidazole resistance in H. pylori.By mutagen-
esis based PCR method, deletion mutations of rdxA 
gene in H. pylori clinical strains were analyzed. The 
assay provided two genotypes; Normal and mutant 
genotypes of rdxA gene with PCR products of 800 
bp and 650 bp in size respectively. Only one sample 
(8%) of the metronidazole resistant H. pylori strains 
exhibited a mutation in rdxA gene which the rest 
of the tested strains exhibited a normal rdxA gene 
(Table 4)
Discussion
H. pylori has been increasingly considered as 
one of the most common bacterial infections af-
fecting all ages worldwide. In Jordan, there is a 
limited number of epidemiological reports with a 
remarkable lack of information regarding the sus-
ceptibility of the clinical strains to the conventional 
antimicrobial agents used for the treatment of H. 
pylori infections [31]. One reason for this shortage 
of information is the technical difficulties of isolating 
this microaerophilic bacterium and the sensitivity of 
the methods used for this purpose [32].
This study has been conducted to characterize 
the susceptibility of the clinical strains of H. pylori 
to the conventional antimicrobial agents used in 
the region with particular concern for metronida-
zole and clarithromycin since there is an increasing 
number of recent reports about the emergence of 
multi-drug resistant H. pylori strains in the develop-
ing countries [33, 34].
Our study reported a very high rate of metroni-
dazole resistance among the clinical isolates of H. 
pylori in Jordan compared to countries from Europe 
and Asia [35-37]. It could be suggested that the mis-
use of metronidazole, which is one of the common 
prescribed drugs by the general practitioners par-
ticularly in adults, would be a major factor for this 
high rate although the differences in gender and 
age were not statistically significant. In addition, the 
chemical nature of this antimicrobial agent plays a 
significant role in selecting the resistant strains. One 
interesting finding of our work is the low occur-
rence in deletion mutations in rdxA gene among 
H. pylori metronidazole resistant strains which is 
similar to data from Japan and supports the stud-
ies which questioned the mutational inactivation of 
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rdxA gene as a key mechanism of metronidazole 
resistance in H. pylori [38]. 
Resistance to clarithromycin was reported in 15% 
of the H. pylori clinical isolates tested in our study. 
This is in agreement with most of the local and 
international studies which reported rates that are 
similar to our results However, the reported MIC 
values of clarithromycin resistant H. pylori in our 
study were higher. [38, 39]. In a study conducted 
by PCR for the detection of point mutations as-
sociated with clarithromycin resistance, similar rates 
were reported in Jordan [31]. Although neither the 
history of treatment failure nor virulence factors of 
the strains could not be statistically established as 
factors for this result, there is mounting evidence 
favoring the testing for the genetic determinants 
with antimicrobial susceptibility testing in cases of 
clarithromycin.
Although testing of fluoroquinolones susceptibil-
ity is not primary in the screening for antibiotic re-
sistance among H. pylori strains, our study showed 
increase rates of resistance to ciprofloxacin and le-
vofloxacin (23% and 8% respectively). Ciprofloxacin 
is widely used in the treatment of many infections in 
our region compared to levofloxacin which is used 
with concern and only prescribed for specific types 
of infections. Our results are in agreement with data 
from other countries which reported higher rates 
for fluoroquinolones resistance among H. pylori 
clinical strains [40, 41]. Further testing for genetic 
determinants should be performed to characterize 
the type of resistance among H. pylori strains to 
ciprofloxacin.
Lastly, the in vitro testing showed that amoxicil-
lin has the least resistance rate where no strains of 
H. pylori exhibited resistance to this antibiotics. In 
addition, the MIC values where less than 0.125 µg/
ml indicating that amoxicillin is a good choice of 
antimicrobial agents that should be included in the 
treatment regimens for H. pylori. In Brazil, resistance 
to amoxicillin has been detected in 29% of strains 
recovered from post-treatment [39]. However, many 
studies from other countries have shown that all 
strains examined are susceptible to amoxicillin [42, 
43]. The clinical significance of amoxicillin suscepti-
bility testing has not been yet documented.
In conclusion, metronidazole resistance among 
clinical isolates of H. pylori is very high. Care should 
be taken into consideration when applying the stan-
dard regimen for the treatment of infections caused 
by this bacterium with emphasis of the importance 
of antimicrobial susceptibility testing in vitro. In ad-
dition, metronidazole use in the triple therapy for 
eradication of H. pylori should be revised. 
The authors declare that there is conflict of 
interests 
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